TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03198013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04195906
Drug: Placebo Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions fo 12 weeks
Study: NCT02637193
Drug: Drug - placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for 16 days
Study: NCT02008318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02095418
Drug: Mycophenolate mofetil, Corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1500mg/day\*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (2 weeks)
Study: NCT02095418
Drug: Corticosteroids, Mycophenolate mofetil
Approvals — FDA: no, EMA: no, PMDA: no
Description: tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1000mg/day\*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (3 month±2weeks)
Study: NCT02236130
Drug: Oral pain medication Acetaminophen with Hydrocodone
Normalized name: acetaminophen / hydrocodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen with Hydrocodone
Study: NCT01105650
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously, 60 mg/kg, days -5 and -4.
Study: NCT03317197
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) only
Study: NCT03317197
Drug: Experimental Group 1
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle)
Study: NCT02281773
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03317197
Drug: Experimental Group 3
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle), Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)
Study: NCT01697020
Drug: Mercaptopurine 20mg/ml oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg
Study: NCT01697020
Drug: Mercaptopurine 50mg tablet
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg
Study: NCT02238223
Drug: Alesion®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03336541
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 ml normal saline) will be administered by intravenous infusion in 40 minutes after childbirth during cesarean delivery.
Study: NCT00440583
Drug: chemotherapy followed by Zevalin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles of chemotherapy with CHOP (Cyclophosphamide iv 750 mg/m2 over 15-45 minutes; Doxorubicin iv 50 mg/m2 over 5-20 minutes; and Vincristine iv 1.4 mg/m2 over 5-15 minutes on day 1 and oral prednisone 40 mg/m2 on days 1-5 repeated every 21 days), followed by Zevalin
Study: NCT01364649
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine Placebo-matching capsules
Study: NCT02114671
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, oral
Study: NCT00280436
Drug: GW679769
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04418141
Drug: CN1
Normalized name: TRACH TUBE,SZ 10 CUFFED SHLY #10CN10R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive CN1 by IV infusion on Day 1 of each cycle (every 3 weeks). The 5 planned dose levels are 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg.
Study: NCT00915057
Drug: NRL972
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of NRL972 administered at baseline, at 3-monthly intervals during treatment for up to 12 months (or the end of treatment) and at 3 and 6 months after the end of treatment.
Study: NCT04621630
Drug: PN-235
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Drug
Study: NCT04621630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT02277769
Drug: Placebo (for Dupilumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
Study: NCT04198298
Drug: EndoSequence
Approvals — FDA: no, EMA: no, PMDA: no
Description: The EndoSequence® retrograde sealing material was used to provide a biologic seal at the apex.
Study: NCT04198298
Drug: Biodentine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Biodentine® retrograde sealing material was used to provide a biologic seal at the apex.
Study: NCT01536223
Drug: TPF (docetaxel plus cisplatin and 5-fluorouracil) group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of TPF neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2,cisplatin75mg/m2 and 5-fluorouracil 2400mg/m2 civ 96 hours .~And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2.
Study: NCT02799602
Drug: Standard ADT (androgen deprivation therapy)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed by the treating physician.
Study: NCT02799602
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching darolutamide (ODM-201) tablets in appearance, bid orally with food, in addition to standard ADT (luteinizing hormone releasing hormone \[LHRH\] agonist/antagonist or orchiectomy) and 6 cycles of docetaxel.
Study: NCT03792191
Drug: Intrathecal Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 15 μg will be administered in the subarachnoid space
Study: NCT02133339
Drug: TRN-157
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02133339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03966170
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo drug
Study: NCT04591626
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01107236
Drug: IW-6118
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT01107236
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of matching placebo for IW-6118 and/or matching placebo for naproxen sodium
Study: NCT01107236
Drug: Naproxen Sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose
Study: NCT00913107
Drug: Lamictal®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The regime of prescription for Lamictal® during the clinical trials was as follows:~1. 50 mg twice daily for 10days, followed by,~2. 100 mg twice daily for the next 10days, followed by,~3. 100 mg thrice daily for the next10 days, followed by,~4. 100 mg four times daily for the final 10 days.
Study: NCT00913107
Drug: Tegretol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The regime of prescription for Tegretol® during the clinical trials was as follows:~1. 150 mg twice daily for 10days, followed by,~2. 200 mg thrice daily for the next 10days, followed by,~3. 300 mg thrice daily for the next 10 days, followed by,~4. 300 mg four times daily for the final 10 days.
Study: NCT01924000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01270048
Drug: mild-ex-gwarip
Approvals — FDA: no, EMA: no, PMDA: no
Description: three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
Study: NCT02994056
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100 mg FDC tablet administered orally once daily
Study: NCT03421860
Drug: cardiac output changes with nor-epinephrine
Normalized name: Sensorcaine with Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: measure cardiac output after giving a bolus of nor-epinephrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
Study: NCT01314742
Drug: Biotene OralBalance® gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biotene OralBalance® gel is dispensed as 42gm, patient specific tube from hospital's Central Pharmacy. One pea-size oral application every 4 hours, or at touch time, to gums and tongue, as long as the subject remains mechanically ventilated for the duration of hospitalization.
Study: NCT04872322
Drug: Percocet Pill
Normalized name: Percocet Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: After surgery participants will be given a prescription for Percocet to be taken as needed for pain
Study: NCT04872322
Drug: Norco Pill
Normalized name: Norco Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: After surgery participants will be given a prescription for Norco to be taken as needed for pain
Study: NCT02061774
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gram of intravenous Acetaminophen
Study: NCT02061774
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator .9% NaCl (sodium chloride) 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours
Study: NCT03526965
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention included pain medications and exercise movements for neck.
Study: NCT00372788
Drug: AZD6244
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral vial
Study: NCT03301909
Drug: Bowel prep combination
Normalized name: bowel prep combination no. 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject may be assigned to any bowel preparation combination.
Study: NCT04578470
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two tablets daily for 13weeks then 1 tablet daily for13 weeks
Study: NCT00855283
Drug: IN NEO
Normalized name: Neosporin Neo To Go!
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Neostigmine via intranasal and sublingual administration
Study: NCT00855283
Drug: IN NEO
Normalized name: Neosporin Neo To Go!
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Neostigmine via intranasal administration
Study: NCT00855283
Drug: IN NEO
Normalized name: Neosporin Neo To Go!
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Neostigmine via intranasal administration
Study: NCT00547573
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet taken by mouth as needed for 12 weeks not more than once a day
Study: NCT00223015
Drug: Fluvastatin, Tacrolimus, Mycophenolat Mofetil
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00904397
Drug: Lidoderm®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
Study: NCT00855283
Drug: IN NEO + IN Glycopyrrolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal or sublingual Neostigmine (at effective dose: 20, 40, or 60 mg) + 4-12 mg intranasal or sublingual Glycopyyrolate
Study: NCT00855283
Drug: IV Visit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg NEO and .4mg GLY given intravenously to see if the subject responds to the intervention. If they respond, then they will proceed to the IN portion of the study.
Study: NCT01925313
Drug: CJ-30044
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20.51mg a day,PO,QD
Study: NCT01925313
Drug: TALION TAB. 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg a day,PO,BID
Study: NCT00904397
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
Study: NCT00978978
Drug: Propofol VS. midazolam and fentanyl, endoscopies, liver diseases
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Intervention group (Propofol): It will be administered as a monotherapy under direct gastroenterologists'~2. Control group (Midazolam with or without Fentanyl): Both drugs will be administered by the gastroenterologists
Study: NCT03559387
Drug: ANF-RHO™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the ANF-RHO™ treatment arm will receive the investigational product on Day 1(day of chemotherapy treatment) of each Chemotherapy cycle. ANF-RHO™ will be administered to the subjects as a subcutaneous injection. Subjects will receive the ANF-RHO™ dose with a volume equivalent to 10 µg/kg, 20 µg/kg and 30 µg/kg.~ANF-RHO™ is provided as a single-use glass vial containing 1.0 ml of solution at a concentration of 5 mg/ml
Study: NCT03559387
Drug: Neulasta®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the Neulasta® treatment arm will receive the comparator drug on Day 2(day after chemotherapy treatment) of each Chemotherapy cycle. Neulasta® will be administered to the subjects at a standard dose of 6.0 mg in 0.6 ml as a subcutaneous injection.~Neulasta® is also provided as a single-use pre-filled syringe.
Study: NCT03673059
Drug: OTC Eczema Moisturizer Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were assigned to use an OTC, oatmeal-containing eczema therapy moisturizing cream twice daily on their face and entire body for the 14-day treatment period of the study, in place of any other moisturizers/emollients. Subjects were also provided with a mild cleanser to use in place of their normal body wash and/or soap (same cleanser as used by Group B) per their usual cleansing routine. After the 14-day treatment period, subjects discontinued use of the moisturizer for the 7-day regression period.
Study: NCT04061265
Drug: lidocaine hydrochloride 2% and epinephrine 1:100000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic agent
Study: NCT02739542
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded drug wallets will be dispensed during routine study appointments in 3 month supply, so that compliance can be reconciled at follow up visits and telephone consultations, and recorded in accountability logs.
Study: NCT00922532
Drug: Inhaled Nitric Oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Nitric Oxide will be administered continuously starting at 20ppm through an INOvent delivery system for up to 14 days.
Study: NCT00922532
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrogen gas will be administered in the same manor as the experimental drug
Study: NCT03094429
Drug: NaBen®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg/day or 1000 mg/day, twice daily
Study: NCT03363269
Drug: ID1201
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01984788
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01395953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
Study: NCT00743197
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 20 mg every night
Study: NCT01104662
Drug: Semi-Synthetic Penicillin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02627027
Drug: Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT02627027
Drug: CKD-395 0.25/750mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT01479478
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo capsule daily.
Study: NCT00313885
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT04620109
Drug: KDR2-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eye drop is in development for the treatment of corneal neovascularization.
Study: NCT04620109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo : the formulation and the product process of placebo are the same as the KDR2-2 eye drops, but without API .
Study: NCT02070744
Drug: Placebo matched to VX-661
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral use
Study: NCT00567307
Drug: Red Heart Pill 2b (Polypill)
Normalized name: Tri-Heart Plus Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A will receive the polypill (Red Heart pill 2b) which is a combination of aspirin (75 mg), simvastatin (20g), lisinopril (10mg) and hydrochlorothiazide (12.5 mg)
Study: NCT01575678
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: blinded capsule 2-4 mg/day, oral use, for 4 weeks
Study: NCT01575678
Drug: Lactose
Normalized name: Lactose
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: blinded capsule 1/day, oral use, for 4 weeks
Study: NCT01096290
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily for 30days, oral
Study: NCT01737320
Drug: short-course antibiotic treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: On day 7 of appropriate intravenous or oral antibiotic treatment for the bacteremic episode (day 1 is the first day of appropriate antibiotic therapy), patients will be randomized to:~1. Intervention group - antibiotic treatment stopped on day 7~2. Control group - antibiotic treatment continued for 14 days according to accepted hospital local guidelines.
Study: NCT01737320
Drug: accepted prolonged antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01611090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form=capsule, route=oral use. Capsule is taken once daily continuously.
Study: NCT02249884
Drug: Urea Dose A
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea cream for topical use.
Study: NCT02249884
Drug: Urea Dose B
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea cream for topical use.
Study: NCT02249884
Drug: Urea Dose C
Normalized name: Urea C 13
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Urea cream for topical use.
Study: NCT02158936
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag matching placebo tablets
Study: NCT02158936
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag matching placebo tablets will be supplied
Study: NCT02602184
Drug: AR/101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02602184
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02259751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00944970
Drug: adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
Study: NCT01151813
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01026961
Drug: Phenylephrine HCL/Acetaminophen/Dimethindene Maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine HCL 10mg/Acetaminophen 500mg/Dimethindene Maleate 1mg
Study: NCT02178709
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRINOX consists of the following combination of drugs:~1. Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle~2. Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle~3. Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle 4.5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.~5.5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle.
Study: NCT01572649
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution for injection~Route of administration: subcutaneous
Study: NCT04254107
Drug: SEA-TGT
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given into the vein (IV; intravenously) on Day 1 of each 21-day cycle
Study: NCT00889590
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg, monthly for 3 months followed by a 3-monthly schedule for up to one year after surgery
Study: NCT01335477
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching BIBF 1120 BID
Study: NCT01335477
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBF 1120 BID (twice daily)
Study: NCT03577626
Drug: Hemay005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemay005 tablets will be taken orally in dose of 52.5mg at fasted dosing on period one followed by fed dosing on period two.
Study: NCT03577626
Drug: Hemay005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemay005 tablets will be taken orally in dose of 52.5mg at fed dosing on period one followed by fasted dosing on period two
Study: NCT04642950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of physiological saline will be administered using inhaler twice daily in approximately 10-15 minutes.
Study: NCT03717064
Drug: RO7049389
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7049389 will be taken orally, in tablet form, BID on Days 1-6 of Period 2.
Study: NCT01298570
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.